Moleculin Biotech announced it received an Australian patent for its preliposomal Annamycin lyophilizate formulation technology, enhancing its intellectual property protection internationally. This patent is part of a broader global portfolio covering Annamycin, an investigational drug for treating acute myeloid leukemia and other cancers. The company aims to strengthen its IP position across key markets to support ongoing clinical development and potential approval. The patent complements Moleculin's efforts to protect multiple aspects of Annamycin's technology worldwide.
Moleculin Biotech's recent Australian patent for its Annamycin formulation technology provides context for health sector trading activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 20:12 WIB: Among 150 priced US health-sector stocks, 82 rose and 64 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 2.41 with a 5.24% gain and 94% buy order activity, Hims and Hers Health Inc (HIMS) at USD 19.77 down 5.00% with 82% sell orders, and BioNano Genomics Inc (BNGO) at USD 1.15 up 4.55% with 56% buy orders.
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
